Clinical and prognostic value of advanced glycation end-products in chronic heart failure.

AIMS Advanced glycation end-products (AGEs) have been proposed as a novel factor involved in the development and progression of chronic heart failure (CHF). We aimed to determine whether plasma levels of N(epsilon)-(carboxymethyl)lysine (CML) and N(epsilon)-(carboxyethyl)lysine (CEL), two well-known AGEs, are related to the severity and prognosis of CHF. METHODS AND RESULTS A total of 102 CHF patients, aged 58 +/- 12 years, with an average left ventricular ejection fraction of 28 +/- 9% were followed for 1.7 (1.2-1.9) years. NYHA functional class and NT-pro-BNP were used as estimates of the severity of CHF. CML and CEL were determined by LC-MS/MS. CML levels were associated with NYHA functional class (P < 0.001) and NT-pro-BNP levels (P < 0.001). Survival analysis for the combined end-point of death, heart transplantation, ischaemic cardiovascular event, and hospitalization for heart failure revealed that CML levels predicted outcome, even after adjustment for age, gender, aetiology of CHF, identified risk modifiers, and several known predictors of outcome in CHF. The predictive value of CML subsided after correction for renal function. CEL was not associated with the severity or prognosis of CHF. CONCLUSION Plasma AGEs, in particular CML levels, are related to the severity and prognosis of CHF. The fact that the relation between CML and prognosis subsided after correction for renal function may suggest that AGE accumulation in renal failure explains part of the prognostic value of renal function in CHF. However, further investigation is warranted to exclude the possibility that CML is just an innocent marker of renal function.

[1]  I. Kubota,et al.  High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. , 2007, Journal of cardiac failure.

[2]  G. Navis,et al.  Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. , 2006, European heart journal.

[3]  C. Visser,et al.  Nϵ-(Carboxymethyl)lysine Depositions in Intramyocardial Blood Vessels in Human and Rat Acute Myocardial Infarction: A Predictor or Reflection of Infarction? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[4]  G. Navis,et al.  Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction , 2006, Circulation.

[5]  L. Hunsicker,et al.  The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension , 2006 .

[6]  Merlin C. Thomas,et al.  Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  Harlan M Krumholz,et al.  Renal impairment and outcomes in heart failure: systematic review and meta-analysis. , 2006, Journal of the American College of Cardiology.

[8]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[9]  J. Nagy,et al.  Serum carboxymethyllysine predicts mortality in hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  L. Hunsicker,et al.  The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  G. Cheng,et al.  C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats , 2005, Acta Pharmacologica Sinica.

[12]  Reindert Graaff,et al.  Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[13]  J. Carlquist,et al.  Cytokines, Interleukin-18, and the Genetic Determinants of Vascular Inflammation , 2005, Circulation.

[14]  A. Smit,et al.  Accumulation of Advanced Glycation End Products, Measured as Skin Autofluorescence, in Renal Disease , 2005, Annals of the New York Academy of Sciences.

[15]  W. Hundley,et al.  The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. , 2005, Journal of cardiac failure.

[16]  M. Laakso,et al.  High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men: A Population-Based 18-Year Follow-Up Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Cirillo,et al.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation , 2004, Heart.

[18]  C. Schalkwijk,et al.  Measurement of Nε-(Carboxymethyl)lysine and Nε-(Carboxyethyl)lysine in Human Plasma Protein by Stable-Isotope-Dilution Tandem Mass Spectrometry , 2004 .

[19]  U. Ott,et al.  Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. , 2004, Kidney international.

[20]  A. Smit,et al.  Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  C. Schalkwijk,et al.  Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. , 2004, Clinical chemistry.

[22]  J. Uribarri,et al.  Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. , 2003, Journal of the American Society of Nephrology : JASN.

[23]  D. Aronson.  Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes , 2003, Journal of hypertension.

[24]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[25]  C. Wanner,et al.  Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.

[26]  T. Miyata,et al.  Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). , 2001, Kidney international. Supplement.

[27]  D. Ingram,et al.  A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Komajda,et al.  Risk stratification in chronic heart failure. , 1998, European heart journal.

[29]  R. Bucala,et al.  Tobacco smoke is a source of toxic reactive glycation products. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Baynes,et al.  N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. , 1997, The Biochemical journal.

[31]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[32]  K. Yamada,et al.  Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. , 1994, Clinical nephrology.